← Leaderboards
Jin-Rong Zhou
Beth Israel Deaconess Medical Center
$4,785,870
Attributed
$4,785,870
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $565.3K · FY2005–12$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$4,785,870 · 12
By mechanism
R01$2,550,825 · 3
R21$1,211,045 · 3
R03$1,024,000 · 6
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Murray A Mittleman$8,077,628
Others in their field
Top investigators on “Gene Expression”
- Jeffrey P Krischer · University Of South Florida$137,481,663
- Eric S Lander · Whitehead Institute For Biomedical Res$128,154,716
- Stacey Gabriel · Massachusetts Institute Of Technology$86,302,566
- Bruce W Stillman · Cold Spring Harbor Laboratory$82,324,317
- Michael P Snyder · Yale University$75,701,723
- Ronald G Crystal · Weill Medical College Of Cornell Univ$74,774,977
Research focus
Gene ExpressionAngiogenesisBiomarkerGenisteinMolecularTumor ProgressionFutureAndrogensScid MouseApoptosisCancer PreventionChemopreventionSoybeansProstatic NeoplasmsMalignant NeoplasmsNutrition Related TagDesignIn VivoMalignant Neoplasm Of ProstateProtocols, TreatmentDietary SupplementsCancer TypeAnimal ModelIncidence
Grant awards (27)
Targeting prostate cancer stem cells to delay prostate cancer progression$227,070
R21 · FY2012 · CA · contact PI
Tanshinones for prevention of bladder cancer progression$87,000
R03 · FY2012 · CA · contact PI
Targeting prostate cancer stem cells to delay prostate cancer progression$189,225
R21 · FY2011 · CA · contact PI
Tanshinones for prevention of bladder cancer progression$87,000
R03 · FY2011 · CA · contact PI
Metabolic Syndrome as Pancreatic Cancer Etiology$229,500
R21 · FY2009 · CA · contact PI
Oldenlandia diffusa for prostate cancer treatment$204,000
R21 · FY2008 · CA · contact PI
Metabolic Syndrome as Pancreatic Cancer Etiology$191,250
R21 · FY2008 · CA · contact PI
Parental metabolic status and offspring cancer risks$85,000
R03 · FY2008 · CA · contact PI
Synergy between phytochemicals for prostate cancer prevention$85,000
R03 · FY2008 · CA · contact PI
Oldenlandia diffusa for prostate cancer treatment$170,000
R21 · FY2007 · CA · contact PI
Synergy between phytochemicals for prostate cancer prevention$85,000
R03 · FY2007 · CA · contact PI
Parental metabolic status and offspring cancer risks$85,000
R03 · FY2007 · CA · contact PI
Chemoprevention of Bladder CA by soybean bioactive comp.$295,489
R01 · FY2006 · CA · contact PI
Chemoprevention of Bladder CA by soybean bioactive comp.$302,600
R01 · FY2005 · CA
Genistien and prevention of HER2-overexpressing breast *$85,000
R03 · FY2005 · CA
Prevention of bladder cancer progression by sulforaphane$85,000
R03 · FY2005 · CA
Chemoprevention of Bladder CA by soybean bioactive comp.$302,600
R01 · FY2004 · CA
Genistien and prevention of HER2-overexpressing breast *$85,000
R03 · FY2004 · CA
Prevention of bladder cancer progression by sulforaphane$85,000
R03 · FY2004 · CA
Genes Modulated by Soy in Prostate Cancer Progression$85,000
R03 · FY2004 · CA
Chemoprevention of Bladder Cancer by soybean$302,600
R01 · FY2003 · CA
Interactions Between Dietary Soy Components &Tamoxifen$297,500
R01 · FY2003 · AT
Genes Modulated by Soy in Prostate Cancer Progression$85,000
R03 · FY2003 · CA
Interactions Between Dietary Soy Components &Tamoxifen$297,500
R01 · FY2002 · AT
Interactions Between Dietary Soy Components &Tamoxifen$297,500
R01 · FY2001 · AT
DIETARY SOYBEAN COMPONENTS AFFECT ON PROSTATE CANCER PRO$230,700
R01 · FY2001 · CA
DIETARY SOYBEAN COMPONENTS AFFECT ON PROSTATE CANCER PRO$224,336
R01 · FY2000 · CA